18 April 2018

Scancell Holdings plc

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has raised £7.5 million through an institutional placing of shares.

LGB Corporate Finance worked closely with the company and its corporate broker, Panmure Gordon, to extend distribution of the issue to a number of wealth management, family office and private investors.

The proceeds of the placing will be used to commence scheduled trials of a vaccine addressing late stage melanoma, support the Cancer Research UK development of the company vaccine against non-small-cell lung carcinoma, commence a first in-human study in patients with triple-negative breast cancer, further the company’s collaboration with BioNTech and initiate a pre-clinical development programme for oesophageal, gastric, pancreatic and colorectal cancers.  These projects demonstrate the broadening scope of the company’s business and its collaborations with tier-1 counterparties in the immuno oncology sector.

Recent Articles

27 June 2019

LGB advises RHEON LABS Ltd on oversubscribed £7 million equity capital raise

LGB Corporate Finance is pleased to announce that it has advised RHEON LABS Ltd on its oversubscribed £7 million Series A equity capital raise.  The transaction was achieved by way of a private placement.  Read more


19 June 2019

Issues of medium term notes (MTNs) arranged by LGB can now be settled in CREST

LGB has made arrangements for the settlement of an issue of MTNs by SRT Marine Systems plc through Euroclear’s CREST settlement system.

Read more


14 June 2019

Canadian IT services company CGI is acquiring SCISYS Group plc

SCISYS Group plc has received a cash offer from Canadian company CGI Inc. The offer price of 254.15p represents a 24.6% premium to yesterday’s closing price and values SCISYS at c£78.9m. Read more